HLA-DQB1*0301 Associated Illnesses
The HLA-DQB1*0301 allele is primarily associated with increased susceptibility to type 1 diabetes and chronic hepatitis B, with emerging evidence for associations with systemic lupus erythematosus (SLE), cervical intraepithelial neoplasia (CIN) with HPV-16 infection, and infliximab immunogenicity in inflammatory bowel disease.
Primary Disease Associations
Type 1 Diabetes (Strongest Evidence)
The HLA-DQB10301 allele (also designated as DQB103:01 or part of the DQ8 haplotype) is one of the most significant genetic risk factors for type 1 diabetes 1, 2:
- When paired with DQA1*03:01, this forms the DR4-DQ8 haplotype (DRB104-DQA103:01-DQB1*03:02), which accounts for up to 90% of type 1 diabetes cases diagnosed before age 30 when present alone or in combination with the DR3-DQ2 haplotype 1
- Critical caveat: Individuals with DRB1*11 or 04 who also carry DQB103:01 are NOT likely to develop type 1 diabetes at a young age 1—this represents a protective context despite carrying the allele
- The allele contributes to risk of developing initial β-cell autoantibodies (insulin autoantibodies or GAD autoantibodies) following environmental triggers 1
- Important limitation: These haplotypes are present in 30-40% of the White population, making them necessary but not sufficient for disease development 1
Chronic Hepatitis B
Multiple studies demonstrate HLA-DQB1*0301 as a susceptibility factor for chronic hepatitis B infection 3, 4:
- The allele frequency is significantly elevated in chronic hepatitis B patients (35.58%) compared to controls (18.87%), with a relative risk of 4.07 4
- Mechanistic insight: DQB1*0301 may facilitate HBV DNA replication, promoting progression to chronic infection and potentially hepatocellular carcinoma 5
- The allele shows particularly strong association in patients with familial history of hepatitis B (29.5% vs 21.1% in controls) 5
Secondary Disease Associations
Systemic Lupus Erythematosus (SLE)
Recent research in Chinese Han populations identified HLA-DQB1*0301 as an independent susceptibility locus for SLE (p = 1.43 × 10⁻⁷) 6. This represents a population-specific finding that requires validation in other ethnic groups.
HPV-16 Associated Cervical Intraepithelial Neoplasia
Women carrying HLA-DQB1*0301 show increased risk of developing high-grade CIN when infected with HPV-16 (odds ratio = 1.8) 7. The allele was significantly more prevalent in CIN III compared to CIN II cases, suggesting a role in disease progression.
Infliximab Immunogenicity in IBD
In Japanese patients with inflammatory bowel disease, HLA-DQB1*03:01 strongly predicts early infliximab discontinuation (hazard ratio = 2.03) and elevated anti-drug antibody levels 8. This represents a pharmacogenomic association relevant for biologic therapy selection.
Type 1 Narcolepsy
HLA-DQB1*03:01 significantly affects age of onset in type 1 narcolepsy across multiple ethnicities, lowering onset age by approximately 3.5 years (p = 1.7 × 10⁻¹⁸) 9. This effect is independent of DQA1 alleles and shows no ethnic heterogeneity.
Clinical Implications
Routine HLA-DQB1*0301 testing is NOT recommended for diagnosis or management of these conditions 1. The guideline evidence is clear:
- HLA typing has limited clinical value for diagnosis or classification of type 1 diabetes 1
- Genetic markers should only be used when patients cannot be clearly classified between type 1 and type 2 diabetes 1
- HLA typing is primarily useful for research studies and risk stratification in clinical trials 1
Exception: HLA typing may provide valuable information for selected diabetes syndromes including neonatal diabetes and MODY 1.